Search Results for "corticosteroids, injectable"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for corticosteroids, injectable. Results 51 to 60 of 97 total matches.

An EUA for Anakinra (Kineret) for COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
. Patients were randomized 2:1 to receive anakinra 100 mg or placebo injected subcutaneously once daily ...
The recombinant interleukin-1 (IL-1) receptor antagonist anakinra (Kineret – Sobi) has been granted an FDA Emergency Use Authorization (EUA) for treatment of hospitalized adults with confirmed COVID-19 pneumonia who require low- or high-flow supplemental oxygen, are at risk of progressing to severe respiratory failure, and are likely to have elevated plasma levels of soluble urokinase plasminogen activator receptor (suPAR). Anakinra has been available in the US for years; it is FDA-approved for multiple indications, including rheumatoid arthritis. Assays for suPAR are...
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e203-4 |  Show IntroductionHide Introduction

OTC Primatene Mist Returns

   
The Medical Letter on Drugs and Therapeutics • Jan 28, 2019  (Issue 1564)
and heart rate. Misuse or abuse of the product by excessive inhalation or IV injection of epinephrine ...
The FDA has approved over-the-counter (OTC) sale of inhaled epinephrine (Primatene Mist – Amphastar), a nonselective alpha and beta agonist, for temporary relief of mild symptoms of intermittent asthma in patients ≥12 years old who have been diagnosed with mild intermittent asthma by a healthcare professional. The original version of Primatene Mist, which was approved by the FDA in 1967, was removed from the market in 2011 because the metered-dose inhaler (MDI) contained ozone-depleting chlorofluorocarbon (CFC) propellants; the new MDI contains hydrofluoroalkane (HFA)...
Med Lett Drugs Ther. 2019 Jan 28;61(1564):9-10 |  Show IntroductionHide Introduction

Mirikizumab (Omvoh) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024  (Issue 1698)
) and upadacitinib (Rinvoq) can be used when first-line drugs are ineffective or not tolerated. Corticosteroids can ...
The FDA has approved the interleukin (IL)-23 antagonist mirikizumab-mrkz (Omvoh – Lilly) for treatment of moderately to severely active ulcerative colitis (UC) in adults. Mirikizumab is the first selective IL-23 antagonist to be approved for this indication. Ustekinumab (Stelara), an IL-12/23 antagonist, was approved for treatment of UC in 2019. The IL-23 antagonist risankizumab (Skyrizi) is approved for treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7   doi:10.58347/tml.2024.1698c |  Show IntroductionHide Introduction

Drugs for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 2019  (Issue 1588)
. CORTICOSTEROIDS — When only a few joints are involved, intra-articular injections of corticosteroids may provide ...
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Med Lett Drugs Ther. 2019 Dec 30;61(1588):203-10 |  Show IntroductionHide Introduction

Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
(frequency ≥20%) of teclistamab in MajesTEC-1 were pyrexia, musculoskeletal pain, injection-site reactions ...
Teclistamab-cqyv (Tecvayli – Janssen), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval was based on response rate. Teclistamab is the first bispecific BCMA-directed CD3 T-cell engager to be approved in the US.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e196-7 |  Show IntroductionHide Introduction

Colchicine and Other Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2009  (Issue 1326)
aspiration of joint fluid and injection of a corticosteroid such as methylprednisolone or triamcinolone ...
Until the recent introduction of febuxostat (Uloric), no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid (Colbenemid, and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Med Lett Drugs Ther. 2009 Nov 30;51(1326):93-4 |  Show IntroductionHide Introduction

Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
, musculoskeletal pain, injection-site reactions, pyrexia, and abdominal pain can occur. Neurologic toxicity ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for subcutaneous treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥2 lines of systemic therapy. Epcoritamab is the second T-cell-engaging bispecific antibody to become available in the US for treatment of non-Hodgkin's lymphoma; mosunetuzumab-axgb (Lunsumio) was recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4   doi:10.58347/tml.2023.1678d |  Show IntroductionHide Introduction

Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
. Injection of voretigene neparvovecrzyl into the subretinal space can potentially restore the visual cycle ...
The FDA has approved voretigene neparvovec-rzyl intraocular suspension (Luxturna – Spark), an adeno-associated virus vector-based gene therapy, for treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy in patients who have viable retinal cells. It is the first gene replacement therapy approved in the US that targets a disease caused by mutations in a specific gene and the first pharmacologic treatment to be approved for this disorder.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):53-5 |  Show IntroductionHide Introduction

Three New Drugs for Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2010  (Issue 1345)
and sites; can be 4 and 24 hrs3,4 pyrexia, injection site suppresses bradykinin repeated if reactions ...
In the past 2 years, the FDA has approved 3 new drugs for prevention or treatment of hereditary angioedema (HAE) in non-pregnant adolescents and adults: the C1 esterase inhibitor Cinryze for prophylaxis and the C1 esterase inhibitor Berinert and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks.
Med Lett Drugs Ther. 2010 Aug 23;52(1345):66-7 |  Show IntroductionHide Introduction

Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016  (Issue 1490)
injection of a corticosteroid is a reasonable alternative. Opioids can be used as a last resort ...
The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam (Mobic, and generics), for management of osteoarthritis pain. According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.
Med Lett Drugs Ther. 2016 Mar 14;58(1490):35-6 |  Show IntroductionHide Introduction